Could oral administration of immunoglobulin reduce diarrheal severity in common variable immunodeficiency?

To the Editor,

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterised by low concentration of serum IgG in association with low serum levels of IgA and/or IgM, despite normal to low number of B-cells and variable T-cells abnormalities.1,2 The patients with CVID could present a variety of clinical manifestations, including autoimmunity, malignancy, and recurrent infections, mainly in respiratory and gastrointestinal (GI) systems.1,3,4

Gastrointestinal manifestations in humoral immunodeficiencies could be due to infection, malignancy, inflammatory disorders or autoimmunity.1,5 The incidence of these manifestations ranges from 20% to 60%. Infections and inflammation leading to malabsorptive symptoms could be seen in about 20% of individuals with CVID, while GI infections with Salmonella, Campylobacter, or Giardia occur in about 10% of individuals.1,2,5 Giardia lamblia is a common cause of diarrhoea in CVID patients. Treatment with metronidazole is generally effective, but often requires a prolonged course, while patients exhibit a high relapse rate, reflecting the inability of the immunodeficient patient to eradicate this organism.5,6

Herein, a 26-year-old woman with CVID is presented, who suffered from persistent chronic diarrhoea and poor weight gain. The patient had a past history of right wrist osteomyelitis caused by pseudomonas at the age of one year. Subsequently, immunological work-up was done for the patient at the same time, as of family history of death in one sibling at the same age with recurrent episodes of bacterial pneumonitis. Quantitative immunoglobulin measurement revealed an IgG of 200 mg/dl, IgA <5 mg/dL, and IgM <10 mg/dL, while lymphocyte enumeration showed normal number of B- and T-cells (Table 1). Further and detailed immunological studies revealed impaired antibody function and absent iso-haemagglutinin titters; hence the diagnosis of hypogammaglobulinaemia was made and monthly intravenous immunoglobulin (IVIG) replacement therapy without prophylactic antibiotics was started. As she continued to have hypogammaglobulinaemia even after four years of age, the diagnosis of CVID was made for her. Eight years later, at the age of nine years, she stopped receiving IVIG; and seven months later, she was admitted to hospital because of unilateral arthritis of left knee, which was treated with empiric antibiotics. IVIG was started again and she has been under regular IVIG therapy since that age.

It should be noted that watery diarrhoea started at one year of age, 3–4 episodes per day with fluctuations in severity, but never improved completely until 25 years of age. Failure to thrive was remarkable. Serum exams were always negative for blood or fat. At the age of 15 years, stool exam revealed Giardia lamblia cyst without trophozoite; hence metronidazole was ordered for 3–4 weeks and continued as a prophylactic daily schedule, but unfortunately no relief from diarrhoea was achieved. Giardia lamblia cyst was constantly present in almost all stool exams since 25 years ago and did not improve with metronidazole or tinidazole. Investigations for other opportunistic organisms such as isospora, cryptosporidiuasis, trichomoniase and other parasites were inconclusive. Barium meal showed enhancement of descending colon earlier than ascending colon, while possibility of a fistulous tract was suggested. Subsequent colonoscopy revealed no fistulous tract, but only mucosal thickening due to chronic Giardia colonisation is considered. Specimens were not suggestive for inflammatory bowel diseases.

During 25 years of receiving monthly IVIG, trough IgG level ranged from 300 to 500 mg/dL without any effective control of diarrhoea and her weight ranged between 30 and 35 kg. Because of frustration about her disabling condition, immunoglobulin therapy via oral consumption was started experimentally with the dose of five grams monthly and continued for previous nine months. Significant and dramatic relief of diarrheal frequency and severity was achieved during this short period of time, while she started to gain weight reaching 37 kg that is 4 kg weight gained during nine months.

Treatment for antibody deficiency syndromes includes administration of immunoglobulin which may reduce the frequency of infections and autoimmune diseases. However,
sometimes GI diseases are not controlled well with IVIG replacement, because these preparations contain IgG which cannot reach the lumen of the intact gut and also contain very little amount of IgA which is a vital component of mucosal defence. Recent experimental evidence suggests that IVIG could exert an effect more than passive substitution of antibodies could do against pathogenic microbes; it rectifies the defective signalling and induces an optimal functioning of cellular compartment, thus re-establishing immune homeostasis. Theoretically, treatment with oral immunoglobulin has not been successful, because IgG is rapidly destroyed before reaching the small intestine. There is an animal study, which showed an induction of oral tolerance by oral administration of IVIG against anti-phospholipid syndrome in naïve mice. The presented case is a unique one, since the patient experienced improvement of chronic diarrhoea following oral administration of IVIG. Our results point to a possible role of oral IVIG in the improvement of chronic diarrhoea in CVID patients, especially in those infested by organisms such as Giardia. However, further original multi-centre studies are needed to test the efficacy of oral administration of immunoglobulin in improvement of diarrhoea severity in those with CVID.

Ethical disclosure

Confidentiality of data. The authors declare that no experiments were performed on humans or animals for this investigation.

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this investigation.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflict of interest

The authors have no conflicts of interest and no funding was received.

References


M. Nabavi a, H. Esmaeilzadeh b, c, S. Arshi a, M. Fallahpour a, N. Mortazavi b, N. Rezaei a, d

a Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran

b Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
c Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
d Molecular Immunology Research Center; and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author.

E-mail addresses: esmailzadeh_ho@yahoo.com, esmailzadeh_da@yahoo.com (H. Esmaeilzadeh).

http://dx.doi.org/10.1016/j.aller.2012.12.008

Desensitisation of the youngest patient with Pompe disease in response to algglucosidase alfa

To the Editor,

Biological agents such as cytokines, monoclonal antibodies and enzymes can cause allergic reactions, which may result in a wide range of clinical symptoms, from light pruritus to anaphylactic shock. Hypersensitivity reactions increase as exposure to biological agents increases. One biological agent that may cause a hypersensitivity reaction is recombinant human acid α-glucosidase (rhGAA). rhGAA is used to treat Pompe disease (PD), which is a rare, progressively debilitating, and often fatal lysosomal storage disorder. Enzyme replacement therapy (ERT) with rhGAA is shown to improve cardiomyopathy, motor skills, and functional independence, and to prolong survival in patients with PD. Other than rhGAA, there are currently no alternative treatments for PD. The present paper proposed a new desensitisation protocol that follows general desensitisation